When was Etcembly founded?

Etcembly was founded in 2020 and raised its 1st funding round within a year of its incorporation.

Where is Etcembly located?

Etcembly is headquartered in Harwell, United Kingdom. It is registered at ATLAS BUILDING FERMI AVENUE,HARWELL CAMPUS,DIDCOT,OXFORDSHIRE,ENGLAND,OX11 0QX.

Who is the current CEO of Etcembly?

Michelle Teng of Etcembly. They have also founded 1 company.

Which legal entities is Etcembly associated with?

Etcembly is associated with ETCEMBLY LTD.

How many employees does Etcembly have?

As of Jul 31, 2026, the latest employee count at Etcembly is 24.

Is Etcembly a funded company?

Etcembly is a funded company, having raised a total of $12.7M across 4 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Jan 22, 2020.

How much is Etcembly worth?

The latest valuation of Etcembly is $***** as of Jun 11, 2023.

When was the latest funding round of Etcembly?

Etcembly's latest funding was a $***** Series A round on Jun 11, 2023, with participation from 0 investor.

Where does Etcembly rank among its competitors?

Etcembly ranks 8th amongst 171 active competitors, of which 50 are funded. It stands 8th in terms of total funding among its competitors. The most recent competitor to raise funding was DBV Technologies, which secured $307M in Apr, 2025.

Who are the top competitors of Etcembly?

Etcembly's top competitors include BeiGene, BioNTech and DBV Technologies. Among them, DBV Technologies secured the most recent funding round in April, 2025.

Etcembly - 2026 Company Profile, Team, Funding, Competitors & Financials

Etcembly is a series A company based in Harwell (United Kingdom), founded in 2020 by Michelle Teng and Jacob Hurst. It operates as a Developer of AI-driven technology for engineering and designing novel immunotherapies. Etcembly has raised $12.7M in funding, with a current valuation of $*****. The company has 171 active competitors, including 50 funded and 39 that have exited. Its top competitors include companies like BeiGene, BioNTech and DBV Technologies.

Company Details

Developer of AI-driven technology for engineering and designing novel immunotherapies. The company offers services for rapid design and engineering of new drug candidates. It designs, optimises, and validates TCRs, antibodies, bispecifics, and VHHs. The company utilises protein language models designed to be both modality- and disease-agnostic. It also conducts long-term cancer survivor studies.

Website: www.etcembly.io/
Social
Email ID: *****@etcembly.io
Phone Number: +44 **********
Registered Address: ATLAS BUILDING FERMI AVENUE,HARWELL CAMPUS,DIDCOT,OXFORDSHIRE,ENGLAND,OX11 0QX

Key Metrics

Founded Year

2020

Location

Harwell, United Kingdom

Stage

Series A

Total Funding

$12.7M in 4 rounds

Latest Funding Round

Series A, Jun 11, 2023, $*****

Post Money Valuation

$***** as on Jun 11, 2023

Ranked

8^th among 171 active competitors

Employee Count

24 as on Jul 31, 2026

Similar Companies

BeiGene & 203 more

View Etcembly's full profile

Etcembly is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
ETCEMBLY LTD CIN: 12059749 , United Kingdom, Active	Jun 18, 2019	-	13 (As on Jun 30, 2022)

Etcembly has raised a total funding of $12.7M over 4 rounds. Its first funding round was on Jan 22, 2020.

Here is the list of recent funding rounds of Etcembly:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jun 11, 2023	7285470	Series A	7384319	5798250	2671082	5694470
May 03, 2022	4313826	Series A	9263979	6664319	6084867	6557672
Nov 16, 2020	6689330	Seed	6334524	4017780	2576984	9432998

Access funding benchmarks and valuations. Sign up today!

View details of Etcembly's funding rounds and investors

The founders of Etcembly are Michelle Teng and Jacob Hurst. Michelle Teng is the CEO of Etcembly.

Here are the details of Etcembly's key team members:

Michelle Teng: Co-Founder & CEO of Etcembly.
Jacob Hurst: Co-Founder & CTO of Etcembly.

View details of Etcembly's Founder profiles and Board Members

Etcembly's employee count trend

Etcembly has 24 employees as of Jul 26. Here is Etcembly's employee count trend over the years:

Uncover Etcembly's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Etcembly include BeiGene, BioNTech and DBV Technologies. Here is the list of Top 10 competitors of Etcembly, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	81/100
2nd	BioNTech 2008, Mainz (Germany), Public	Developer of immunotherapeutics for the treatment of cancer and other diseases	$861M	Fidelity Investments, Redmile Group & 28 others	69/100
3rd	DBV Technologies 2002, Bagneux (France), Public	Developer of products for the treatment of various kinds of food allergies	$68.9M	Sofinnova Partners, Lundbeck Foundation & 16 others	68/100
4th	Serum Institute of India 1966, Pune (India), Funding Raised	Manufacturer of vaccines and immuno-biological drugs for infectious diseases	-	Fortune Intercontinental, Cyrus Poonawalla Family Trust ... & 9 others	62/100
5th	AC Immune 2003, Lausanne (Switzerland), Public	Developer of antibodies, small molecules, and vaccines for Alzheimer’s disease and other neurodegenerative diseases	$120M	BVF Partners, Redmile Group & 4 others	61/100
6th	Vir Biotechnology 2017, San Francisco (United States), Public	Developer of therapeutics for the treatment of infectious diseases	$216M	Gates, Arch Venture Partners & 12 others	59/100
7th	Cidara Therapeutics 2013, San Diego (United States), Acquired	Developer of novel anti-infectives for infectious diseases (bacterial and fungal)	$78.4M	5AM Ventures, Perceptive Advisors & 25 others	58/100
8th	Etcembly 2020, Harwell (United Kingdom), Series A	Developer of AI-driven technology for engineering and designing novel immunotherapies	$12.7M	-	57/100
9th	Epitopea 2021, Cambridge (United Kingdom), Seed	Developer of immunotherapeutics for the treatment of cancer	$44.6M	Advent Life Sciences, Cambridge Innovation Capital ... & 9 others	57/100
10th	Tiziana Life Sciences 1998, London (United Kingdom), Public	Developer of small-molecule drugs for cancer and autoimmune diseases	-	-	56/100